-
Pharmacology
-
- Enzymes
-
- ATPase & GTPase
- Caspase
- Cholinesterase
- Coenzymes
- Cyclase
- Cyclooxygenase
- Cytochrome P450
- Deacetylase
- Dehydrogenase
- Demethylase
- Hydrolase
- Isomerase
- Kinase
- Oxidases
- Oxygenase
- Phosphatase
- Phosphodiesterase
- Phospholipase & Lipase
- Polymerase
- Protease
- Reductase
- Secretase
- Synthetase & synthase
- Telomerase
- Transaminase
- Transferase
- Ion Channels
- Receptors & Transporters
-
- Adenosine
- Adrenoceptors
- Cannabinoid
- Catalytic Receptors
- Chemokine
- Dopamine
- Enzyme-Linked Receptors
- G protein-coupled estrogen
- GABA
- Glutamate
- Glycine
- Histamine
- Imidazoline
- Inositol triphosphate receptor
- Melatonin
- Muscarinic
- Nicotinic
- Nuclear Receptors
- Opioids
- Peptide Receptors
-
- Angiotensin
- Apelin
- AXOR
- Bombesin
- Bradykinin
- CCK
- Endothelin
- Galanin
- Ghrelin
- Glucagon and Related Receptors
- LHRH
- Melanocortin
- Melanocyte Stimulating Hormone
- Motilin
- Neuromedin
- Neuropeptide FF/AF Receptors
- Neuropeptide S
- Neuropeptide Y
- Neurotensin
- Orexin
- Other
- Oxytocin
- PAR
- Secretin receptor
- Sensory Neuron Specific Receptor
- Somatostatin
- Substance P
- Tachykinins
- Vasopressin
- VIP
- Prostanoid
- Purinergics
- Serotonin
- Sigma
- Smoothened
- Sphingosine 1-Phosphate Receptors
- TGR5
- Toll-like Receptors
- Transporters
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Epigenetics
- Extracellular matrix & cell adhesion
- Heat Shock Proteins
- Immunomodulators
- Lipid signaling
- Signal transduction
- Stem Cells
-
Research Area
-
- Addiction
- Alzheimer's Disease
-
- Apoptosis & cell cycle
- Cytoskeleton & motor proteins
- Glutamate
- Immunomodulators
- Muscarinic
- Nicotinic
- Nitric oxide signaling
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Immunomodulators
- Lipid signaling
- Signal transduction
- Stem Cells
- Cancer
-
- Angiogenesis
- Apoptosis & cell cycle
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Epigenetics
- Extracellular matrix & cell adhesion
- Nuclear Receptors
- Signal transduction
- Depression
- Diabetes
-
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- Immunomodulators
- Nitric oxide signaling
- Other
- Potassium
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Immunomodulators
- Lipid signaling
- Signal transduction
- Stem Cells
- Sodium
- TRP
- Heart disease
-
- Adenosine
- Adrenoceptors
- Apoptosis & cell cycle
- Ca2+ signaling
- Calcium
- Cytoskeleton & motor proteins
- Immunomodulators
- Nitric oxide signaling
- Nuclear Receptors
- Other
- Potassium
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Coenzymes
- Cytokine and NF-κB signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Hedgehog signaling
- Immunomodulators
- Inositol & cAMP signaling
- Lipid signaling
- Nitric Oxide
- Stem Cells
- Sodium
- TRP
- Hypertension
-
- Adrenoceptors
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- Immunomodulators
- Nitric oxide signaling
- Nuclear Receptors
- Other
- Peptide Receptors
- Potassium
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Immunomodulators
- Lipid signaling
- Signal transduction
- Stem Cells
- Sodium
- TRP
- Obesity
-
- Apoptosis & cell cycle
- Ca2+ signaling
- Cannabinoid
- Cytoskeleton & motor proteins
- Immunomodulators
- Muscarinic
- Nitric oxide signaling
- Other
- Peptide Receptors
- Potassium
- Serotonin
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Immunomodulators
- Lipid signaling
- Signal transduction
- Stem Cells
- Sodium
- TRP
- Pain & inflammation
-
- Apoptosis & cell cycle
- Ca2+ signaling
- Cannabinoid
- Cytoskeleton & motor proteins
- GABA
- Glutamate
- Histamine
- Immunomodulators
- Nitric oxide signaling
- Opioids
- Other
- Peptide Receptors
- Potassium
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Coenzymes
- Cytokine and NF-κB signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Hedgehog signaling
- Immunomodulators
- Inositol & cAMP signaling
- Lipid signaling
- Nitric Oxide
- Stem Cells
- Sodium
- TRP
- - Parkinson's Disease
- Respiratory disease
-
- Adenosine
- Adrenoceptors
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- Histamine
- Immunomodulators
- Muscarinic
- Nitric oxide signaling
- Other
- Peptide Receptors
- Potassium
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Coenzymes
- Cytokine and NF-κB signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Hedgehog signaling
- Immunomodulators
- Inositol & cAMP signaling
- Lipid signaling
- Nitric Oxide
- Stem Cells
- Sodium
- TRP
- Schizophrenia
- Stress / Anxiety
- Stroke
-
- Adenosine
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- Glutamate
- Immunomodulators
- Nitric oxide signaling
- Nuclear Receptors
- Other
- Potassium
- Signaling
-
- Amyloidogenesis
- Angiogenesis
- Apoptosis & cell cycle
- Ca2+ signaling
- Cytoskeleton & motor proteins
- DNA, RNA & protein synthesis
- Endocytosis & exocytosis
- Heat Shock Proteins
- Immunomodulators
- Lipid signaling
- Signal transduction
- Stem Cells
- Sodium
- TRP
We have 259 products in: Biochemicals >> Research Area >> Parkinson's Disease
Parkinson's Disease beginning with A - C |
Code | Name | Details | Image Abreview Publication |
|---|---|---|---|
| Highly selective D4 agonist Purity: > 98% |   | ||
| Endogenous neurotransmitter active at acetylcholine receptors | | ||
| Dopamine agonist Purity: > 99% | | ||
| Fluorescent β2 adrenoceptor antagonist Purity: > 97% |  | ||
| mGlu7 agonist Purity: > 99% |  | ||
| AMPA agonist Purity: > 99% | | ||
| AMPA agonist Purity: > 98% | | ||
| Potent nicotinic agonist Purity: > 98% | | ||
| AMPA receptor potentiator Purity: > 99% | | ||
| Broad spectrum glutamate antagonist Purity: > 99% | | ||
| Selective group III mGlu agonist Purity: > 99% | | ||
| Broad spectrum glutamate antagonist; water soluble Purity: > 99% | | ||
| NMDA glutamate site antagonist Purity: > 99% | | ||
| NMDA glutamate site antagonist Purity: > 99% | | ||
| NMDA glutamate site antagonist. Water soluble form. Purity: > 99% | | ||
| Partial dopamine D2 agonist Purity: > 99% | | ||
| Multiple receptor antagonist. Anti-psychotic agent. Purity: > 99% | | ||
| β1 adrenoceptor antagonist Purity: > 99% | | ||
| Selective β1 adrenoceptor antagonist Purity: > 98% | | ||
| Selective α2 adrenergic receptor antagonist Purity: > 99% | | ||
| Selective β1 antagonist Purity: > 99% | | ||
| 5-HT1A partial agonist. α-adrenoceptor antagonist. Purity: > 99% | | ||
| Non-selective, potent adrenoceptor antagonist Purity: > 99% | | ||
| Selective 5-HT1D receptor antagonist Purity: > 98% | | ||
| Selective, high affinity 5-ht1e and 5-HT1F receptor agonist Purity: > 99% | | ||
| Potent, selective D2-like dopamine receptor agonist Purity: > 99% | | ||
| Subtype-selective α7 nAChR antagonist Purity: > 99% | | ||
| Potent non-selective β adrenoceptor antagonist Purity: > 99% | | ||
| Non-selective DAT/NET inhibitor Purity: > 98% | | ||
| 5HT1A agonist. Anxiolytic. Purity: > 99% | | ||
| D2-like receptor agonist Purity: > 99% | | ||
| Potent β and α1-adrenoceptor antagonist Purity: > 99% | | ||
| PAM for mGlu5. Active in vivo. Purity: > 98% | | ||
| Competitive NMDA antagonist Purity: > 99% | | ||
| Competitive NMDA antagonist Purity: > 99% | | ||
| NMDA receptor glycine site antagonist Purity: > 99% | | ||
| NMDA receptor glycine site antagonist; water soluble Purity: > 99% | | ||
| AMPA / kainate agonist Purity: > 98% | | ||
| Potent H1 antagonist and SNRI Purity: > 99% | | ||
| Typical antipsychotic. Non-selective receptor antagonist. Purity: > 99% | | ||
| Selective mGlu5 agonist Purity: > 98% | | ||
| mGlu5 agonist; water soluble Purity: > 99% | | ||
| β-adrenoceptor agonist Purity: > 99% | | ||
| 5-HT4 receptor agonist. hERG blocker. Purity: > 99% | | ||
| 5-HT reuptake inhibitor Purity: > 98% | | ||
| α2 adrenoceptor agonist Purity: > 99% | | ||
| Atypical antipsychotic Purity: > 98% | | ||
| AMPA / kainate antagonist Purity: > 99% | | ||
| AMPA / kainate antagonist (water soluble) Purity: > 99% | | ||
| Highly potent, selective 5-HT1B agonist Purity: > 98% | | ||
| Selective, non-competitive mGlu1 antagonist Purity: > 98% | | ||
| Potent NMDA antagonist | | ||
| Potent NMDA antagonist | | ||
| Potent competitive NMDA antagonist Purity: > 98% | | ||
| Potent group II/III metabotropic glutamate receptor antagonist Purity: > 99% | | ||
| NMDA glycine site agonist Purity: > 99% | | ||
| AMPA receptor desensitisation inhibitor Purity: > 98% | | ||
| Potent H1 and 5-HT2B antagonist. Non-selective receptor antagonist. Purity: > 99% | | ||
| Potent, selective nAChR agonist Purity: > 99% | |